Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Totally agree Biffa. The problem for me (and a lot more, I suspect) is that even if the share price doubles I am still under water. And I am 'buttered' if I am going to stick in another penny while the shares are behaving like they do
Very bullish EMV First qtr newsletter just out.
Well worth a read.
Still can't quite believe we have only gained 1p on that news.
If they are going to sell the lot this summer for £10M in cash? then I hope they put a share buy back into the mix post results.
About time they started narrowing the discount of the 60p share price to the £2.00 asset value.
Nsci is delivering stunning capital growth as the exit some of these investments I am sure we will see elements of Capital distributions. They gave some heavy hitters in their portfolio insane that you can buy at below a third of NAV
This is a brilliant long term investment. Buy them under 60 and forget them. One day it will cash in one of these stakes for 50 times what it cost
Nsci’s biggest problem is that the only way to really deliver tangible returns for shareholders is via capital growth. That’s only going to come from a huge revaluation of its assets, so that the disconnect between its current mkt cap and its underlying NAV, becomes so huge that there’s no choice but for it to be recognised in an increased share price, or through the sale of one or more of its investments and a return of cash to shareholders as a special dividend, or through a floatation of same with Nsci shareholders being granted shares in a new company at the time of spin out.
It’s just not properly understood by the investor landscape yet, and the mgt team don’t seem that bothered to do anything to really sell NSCI to a wider audience …
Very frustrating
L.
There is only new money of 550k - the rest is conversions so its a tad misleading
Couldn't agree more.
Mr. Market is clearly in need of a double dose of Fluoxitine.
That is one fooking brilliant RNS.
Fair value up from £3.5M to £8M+
That is almost a third of todays Market Cap FFS!
Well done to the NSCI team.
If the market was actually working we would be +15/20p today.
Mark it down on shtt trades and ignore a decent 25k buy.
Modest increase on last years fair value of £41.8M (Dec 22) so lets say £45M or £1.80 a share.
MCap at 60p is £15M
Complete joke.
Start a buy back or make us a decent offer.
Almost all of their investments are finally on the up.
Not performing well - talk of raise required on Stockwits. £5m value atm puts a tad of pressure on the mcap given the permanent NAV disconnect. On my watchlist atm
Ventive 11%, EMV 25%
From Pipehawk half year 27/03/2024. They are one of the production partners for the new heat pump.
Recruitment has been a challenge as we have increased our staff levels to support the pending build profile of the contract manufacturing solutions. Inflation and cost of living increases have resulted in increased salary demands across the business. We have seen an increase of staff from 55 to 75 with more resource being required to support the contract manufacturing aspect of the business for both Caudwell Marine and Ventive, as well as considerations for Fast MDX, moving in to the latter stages of 2024. Commencement of contract manufacturing has suffered delays for the above reasons, but is moving ever closer. Caudwell is targeting start of production in July this year which will generate additional revenue towards the latter stages of 2024. In addition, Ventive has production targets on a similar timeframe.
QBot 15%, EMV 32%
USA and Europe.
Q-Bot, the UK construction tech company that uses robotics and AI to insulate people’s homes, has strengthened its Board with the appointment of a new Executive Chair and a second Investment Director.
Victor Vadaneaux has been appointed Executive Chair of Q-Bot. Victor has worked within B2B services, the engineering industry and the healthcare sector, and has extensive business and private equity experience of the UK, EU and US markets, including several successful exits.
Malcolm Groat has been appointed an Investment Director of Q-Bot, to work alongside Dr Ilian Iliev, the company’s existing Investment Director. Malcolm has more than 25 years of experience as a Chair, NED, CFO, and CEO in the public and private markets.
These senior board appointments significantly enhance Q-Bot’s capabilities and take place at an exciting time for the company and the construction industry. Using AI and robotics, Q-Bot’s insulation is deployed beneath suspended timber floors or to the underside of suspended concrete floors. In the UK alone, Q-Bot’s high performance retrofit insulation can help insulate the 8 to 12 million homes that have suspended floors and which are hard to treat using traditional forms of insulation. In the UK, Q-Bot’s customers include social housing landlords, energy companies and private homeowners. Internationally, the company has identified a further multi-billion market for robotics-based retrofit of insulation to residential homes in North America and North West Europe.
Victor and Malcolm will help Q-Bot to scale its robotics-as-a-service sales in the UK and expand its digital retrofit service. As its next phase of growth, Q-Bot is set to launch in the US and scale in the EU through strategic partnerships.
Their appointments have been facilitated by EMV Capital, a key investor in Q-Bot, and the company continues to draw on the value creation services provided by EMV Capital.
Have now launched SageTech Veterinary with a massive partnership.
At SageTech Veterinary, we are committed to eliminating waste, pollution and unnecessary environmental harm caused by volatile anaesthetic agents.
Our mission is to provide veterinary clinics with a safe, sustainable and easy to use solution for the capture, recovery and recycling of these agents, to lower their carbon footprint, and help to protect the planet for future generations.
SageTech Veterinary - Leading Sustainable Anaesthesia.
Find out more at www.sagetechveterinary.com
We are delighted to share our portfolio company SageTech Medical, the sustainable anaesthesia provider, has announced a partnership with Mars Veterinary Health and its UK veterinary clinic group Linnaeus.
A veterinary-industry first, Mars Veterinary Health’s one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts.
SageTech on a roll. We hold 5.5%, EMV 32%.
Recently SageTech Medical delivered 10 SID-Dock waste volatile anaesthetic gas capture machines to Cromwell Hospital.
Another successful delivery and installation for SageTech Medical!
We are pleased to announce that last week we installed our SID-Dock waste volatile anaesthetic gas capture machine at Benenden Hospital!
Benenden are helping to lead the way in delivering sustainable anaesthesia and are the first independent private hospital to adopt our technology!
Our SID-Dock waste volatile anaesthetic gas capture machine was recently installed at Castle Hill Hospital in Hull!
Our SID-Dock waste volatile anaesthetic gas capture machine was recently installed at Crosshouse Hospital in Scotland!
March Portfolio & Investment News
As we approach the end of an eventful Q1, the EMV Capital and NetScientific PLC Group is pleased to share the latest highlights across its deep tech and life sciences portfolio:
➡ Q-Bot Ltd has strengthened its Board with the appointment of Malcolm Groat as its second Investment Director, and a new Executive Chair to be announced shortly.
➡ ProAxsis has appointed EMV Capital and an external adviser to explore options for a potential sale of the company to a new strategic owner to scale the business to its full potential.
➡ SageTech Medical SID-Dock waste volatile anaesthetic gas capture machine was recently installed at NHS Ayrshire & Arran University Hospital Crosshouse and Hull University Teaching Hospitals NHS Trust Castle Hill Hospital. The company is now concentrating on the veterinary market, which represents a significantly higher emissions footprint compared to hospitals.
➡ Vortex Biosciences is focused on generating tightly scoped studies with leading researchers to highlight evidence of the technology to pharma and biotech customers.
➡ PDS Biotechnology has reported its 2023 financial results and outlined its clinical development strategy, which includes Phase 3 plans to address the growing incidence of advanced HPV+ HNSCC after FDA guidance.
➡ Ventive Limited and Q-Bot Ltd exhibited at the Futurebuild 2024 conference, where they showcased their innovative built environment solutions.
👇 Subscribe to our newsletter for more insights and updates: https://lnkd.in/etxzjW6J
Most impressed by the 2 presentations today.
So much going on it's difficult to keep up.
Pretty sure this will be moving a lot higher over the next few months.
Https://www.edisoninvestmentresearch.com/?ACT=18&ID=19709&LANG=
Nice posts biffa. Looking at revisiting NSCI - I think Proaxis may be the dark horse that may kick start the sp - I re-read the old Edison report which valued it at £6m for 56%. Overall, I think the market for NSCI will begin to reflect its advances esp in the light of low valuations and M&A trend. Just a feeling.
My main concern is the lack of proactive marketing of the company - new broker should produce a hefty report going into detail on all investments and explain exactly the benefits of capital under advisory or whatever its called.
Then, if they get the sp up, they can do a modest placing for £2m and use that to expand nearer term opps.
Head of Heat Pumps
Ventive is hiring for a senior role as Head of Product for the upcoming production launch of our new Heat Pump for the Domestic market. Core to the design, manufacturing and commercialization of this technology, the successful candidate will be responsible for delivering an exceptional solution that meets the target market requirements. The Heat Pump uses an innovative modular design that results in significant benefits in this rapidly growing market. The company has advanced interest from UK and EU clients and distributors.
Type: Permanent
Location: Midlands/London/Hybrid
Salary: Package: 80-100k FTE, bonus and equity options
Application deadline: 26th January 2024
Ventive is a dynamic, VC-backed company that specialises in intelligent & renewable Building Services, such as its intelligent Heat Pump systems that provide heating, hot water, cooling and fresh air. The company’s vision is to become the energy platform of modern buildings: creating comfortable and healthy internal environments without costing the Earth. The company has a successful track record in bringing innovative energy/ventilation technologies to market, and has assembled a supply chain for the design and launch of it’s new Heat pump.
Assume we will get an update on the Heat Pump prior to the start of Future build on Tuesday?
Ventive is back showing our full suite of Building Services products: Intelligent Ventilation, Heating and Cooling solutions that autonomously react to the environment - creating comfort without costing the Earth.
We will be unveiling our latest all-in-one Heat Pump, following years of development and welcome you to come and meet the team behind this innovative technology.
From last years fundraise.
The proceeds of the Investment will support the completion of the design and test phase and factory build for Ventive's modular heat pumps, further enhancements to its passive air ventilation product range, and build-up of its marketing and sales capacity to drive sales of its existing product range. The Ventive balance sheet is also streamlined following the conversion of the convertible loans.
Following completion of the Investment, the total equity holding of the NetScientific group in Ventive is 11.0% on a fully diluted basis, which includes the partial settlement of its corporate finance fees relating to the Investment. This holding equates to a post-investment fair value of GBP893,000, a substantial increase of 1,617% from the GBP52,000 reported as at 31 December 2022. In addition, following the introduction of investors to Ventive by EMV Capital under its capital efficient model, NetScientific's capital under advisory with Ventive is now 23.8% of the fully diluted share capital.
Ventive designs and manufactures intelligent heating and ventilation solutions to make buildings healthy, comfortable, efficient, and affordable. Its products address two high priority markets segments: air quality and sustainable heating.
Ventive's passive air ventilation system has been delivered to over 30 schools and five leisure centres, achieving excellent air quality results. Its novel heat pump product, which is in advanced stages of development, is a comprehensive solution for residential applications, with a unique modular design and a novel thermal store. Momentum for the business is underpinned by significant regulatory changes, increasing energy prices, and climate change policies.
Just out.
February Portfolio & Investment News
Throughout February, the EMV Capital and NetScientific PLC group have seen further developments in its deep tech and life sciences portfolio, and continue building a robust team:
▶ EMV Capital has strengthened its operational team with several new hires, including Andrew Maylor as Consulting Associate, Josh Smith as Private Client Manager, and Selina Frost as Client Services Manager.
▶ Q-Bot Ltd has welcomed John Burley as its new CTO to advance the use of robotics, digital and AI in the retrofit and construction sectors.
▶ ProAxsis has welcomed Matthew Blow as its new Head of Commercial and Business Development. The company is now expediting its Point of Care range in the $5.8 billion global respiratory disease testing market.
▶ PointGrab has welcomed Nathan Toms as its new Sales Director overseeing EMEA and North America.
▶ SageTech Medical has made further progress in commercial discussions in the European human and UK veterinary markets.
▶ Dr ILIAN ILIEV, MD of EMV Capital, participated in the Verbier ConstructionTech Summit 2024 focused on the future of construction and sustainability. With presentations from Q-Bot Ltd and Ventive Limited, the event was organised by our partners Shibumi International and IMPULSE PARTNERS - A FAST LANE FOR INNOVATION.
▶ Edward Hooper, Director of EMV Capital, participated in a panel discussion at the British Private Equity & Venture Capital Association (BVCA) First-Time Fundraising Forum on 29 February, providing valuable insight into raising funds from LPs.
▶ EMV Capital is now directly authorised and regulated by the Financial Conduct Authority with firm reference number 982590.
The whole portfolio is on the up.
Nothing from Proaxis for almost a year and then in the last month they have kicked out the useless CEO, hired about 10 people and gone into overdrive on Instagram etc etc.
I follow a couple of the USA investors who specialise in biotech.
Pretty sure PDSB is about to go parabolic!
Agree biffa, so much to be excited about here but unfortunately until they get something over the line and crystalize a substantial profit we will be ignored. Could be tomorrow but also weeks or months. When it does come it will be a very sharp rise! GLA
Looks like another massive 2M plus volume day at PDSB.
Over $20M up on the day, so £800k to NSCI and we actually went down.
I am so looking forward to the day that PDSB just goes vertical and we double on the news.
AIM and the UK market in general is the worst I have ever seen in 30 years.